AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00677118
Drug: Cisplatin,fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
Trial: NCT00473551
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
Trial: NCT01023321
Drug: GLPG0555
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses, oral solution
Trial: NCT01023321
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution
Trial: NCT01023321
Drug: GLPG0555
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, oral solution, 7 or 14 days
Trial: NCT01023321
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, oral solution, 7 or 14 days
Trial: NCT02605239
Drug: Bleaching teeth
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleaching teeth with carbamide peroxide 10% for 3 weeks
Trial: NCT02393755
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01741974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Trial: NCT03757364
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
Trial: NCT01481597
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
Trial: NCT03818945
Drug: shofu PRG barrier coat
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
Trial: NCT01255475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo
Trial: NCT02521207
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00780832
Drug: Anticholinergic medication
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detrol LA 4mg. orally, once daily for 30 days
Trial: NCT02983708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02502253
Drug: grape seed polyphenolic extract, resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
Trial: NCT00216437
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01625026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to obeticholic acid
Trial: NCT00680121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03473314
Drug: Nitric Oxide gas at 160ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
Trial: NCT00651560
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
Trial: NCT03863457
Drug: Fluoroglutamine [18F]F-GLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
Trial: NCT04526496
Drug: Placebo, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to FTP-198, oral suspension
Trial: NCT01139164
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other malignancies not addressed in A or C
Trial: NCT01796197
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01796197
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02265653
Drug: BIIL 284 BS tablet C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265653
Drug: BIIL 284 BS tablet D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00699751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 6 IV administrations separated by 4 weeks intervals.
Trial: NCT00699751
Drug: Best standard of care (BSoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
Trial: NCT00130364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus vehicle cream (placebo)
Trial: NCT02945215
Drug: IBI301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI301 375mg/㎡
Trial: NCT03897088
Drug: PART 1: Double-blind Placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all eligible subjects will receive either tildrakizumab or placebo
Trial: NCT00626548
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg once daily oral dose
Trial: NCT00626548
Drug: Palcebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Plcebo oral tablet once daily
Trial: NCT01976182
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
Trial: NCT01976182
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
Trial: NCT00048581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
Trial: NCT01661270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
Trial: NCT03834519
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04484428
Drug: K-285
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
Trial: NCT01993875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
Trial: NCT01662466
Drug: Testosterone cream (0.5mg per gram)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
Trial: NCT01662466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrier cream without added testosterone in the identical type of pump
Trial: NCT03811080
Drug: DWP14012 A mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Trial: NCT03811080
Drug: DWP14012 B mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Trial: NCT03811080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Trial: NCT03125200
Drug: ADCT-502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT04534218
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg per os, daily, for 6 months
Trial: NCT04534218
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625mg/m²/orally twice daily continuously for 6 months
Trial: NCT00647816
Drug: Inderal® LA Capsules 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg, single dose fasting
Trial: NCT01439893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Trial: NCT01658943
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01002690
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/day orally for 10-13 days
Trial: NCT02706184
Drug: E. coli Nissle suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive E. coli Nissle suspension
Trial: NCT02706184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00274326
Drug: SR121463B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00681720
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral solution or capsule. 3 times per subject.
Trial: NCT02929667
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard 6 weeks titration, starting 10 mg per day.
Trial: NCT02929667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 6 weeks titration.
Trial: NCT01070498
Drug: Trichuris suis ova (TSO)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
Trial: NCT03607487
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB054707 tablet administered orally once daily at the protocol-defined dose.
Trial: NCT03607487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered orally once daily.
Trial: NCT04555577
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03895996
Drug: AVT001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous dendritic cell therapy
Trial: NCT03507257
Drug: Fluorodeoxyglucose
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Trial: NCT02023567
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
Trial: NCT01886313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02837965
Drug: treatment with topical superpotent corticosteroid therapy
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05113420
Drug: Troxevasin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutin
Trial: NCT01880502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose administration
Trial: NCT01567956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
Trial: NCT01179490
Drug: SyB L-0501
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
Trial: NCT01179490
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
Trial: NCT00683995
Drug: KW-2246 (fentanyl citrate)
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: KW-2246 (fentanyl citrate)
Trial: NCT00005073
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02761980
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 250 mg / Acetaminophen 500 mg
Trial: NCT02761980
Drug: Ibuprofen 250 mg
RxNorm normalized name: ibuprofen 250 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 250 mg
Trial: NCT02761980
Drug: Acetaminophen 500 mg
RxNorm normalized name: acetaminophen 500 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 APAP 500 mg caplet
Trial: NCT03423667
Drug: Lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator.
Trial: NCT04076059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04076059
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
Trial: NCT02146430
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 15 mg tablet for oral administration
Trial: NCT02146430
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (matching DS-5565) for oral administration
Trial: NCT04625725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (× 2IM injections) of saline placebo on parent study Day 1.
Trial: NCT04578158
Drug: Standard COVID-19 care
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard covid-19 care as per the hospital/physician guidelines
Trial: NCT02677896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01469364
Drug: Aztreonam Lysine for Inhalation (AZLI)
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
Trial: NCT00071097
Drug: TMC114/rtv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg TMC114/100mg rtv once daily
Trial: NCT00071097
Drug: TMC114/rtv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg TMC114/100mg rtv both twice daily
Trial: NCT00071097
Drug: TMC114/rtv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg TMC114/100mg rtv once daily
Trial: NCT00071097
Drug: TMC114/rtv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg TMC114/100mg rtv twice daily
Trial: NCT02592161
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks
Trial: NCT01893905
Drug: CS+SG
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
Trial: NCT04233866
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01893905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
Trial: NCT04233866
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04233866
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00316745
Drug: Campto, Topotesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
Trial: NCT00316745
Drug: Isovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-leucovorin (200mg/m2) Day 1, 15
Trial: NCT04533022
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 b.i.d.
Trial: NCT02441972
Drug: 18F-Al-NOTA-PRGD2 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
Trial: NCT01064349
Drug: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab or Lapatinib
Trial: NCT03801876
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folinic acid, flurouracil and oxaliplatin
Trial: NCT03801876
Drug: CAPOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine combined with oxaliplatin
Trial: NCT03801876
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT01010178
Drug: Macrolid, Theophylline, Inhaler Corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we have no permission to include them in detail because of privacy policy of mentioned journal for publication
Trial: NCT00354744
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV
Trial: NCT00354744
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV
Trial: NCT02658825
Drug: Placebo (Matching with Moxifloxacin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
Trial: NCT00989352
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3g/m² i.v. max. 9 times
Trial: NCT02236715
Drug: Atrovent®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01762748
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).